UNH Stock Rallies on Strong Q2 Earnings, But DOJ Cloud Lingers
UnitedHealth stock (UNH) has made a remarkable recovery from its 2025 lows, surging roughly 60% over the past year. The turnaround began in July 2026 when UnitedHealth reported second-quarter earnings that blew past Wall Street's estimates, with revenue reaching $112.0 billion and adjusted earnings per share hitting $6.38.
The key driver of this performance was a significant drop in the medical care ratio (MCR), which fell to 86.7% from 89.4% a year earlier. This decrease signaled that Medicare Advantage utilization is finally normalizing, a major concern for investors last year.
Management raised its full-year profit outlook to $19.50-$20.00 per share and increased the buyback target to at least $5 billion. With shares trading near $410, UNH trades around 20 times forward earnings, which is considered reasonable for a scaled healthcare company like UnitedHealth.
However, not everyone is convinced that this recovery will last. Some analysts point out that expectations are high after the strong Q2 earnings and that the next catalyst - Q3 earnings in early October - carries a consensus estimate of $3.74 per share, which could be a step down from the previous quarter's result.
The ongoing Department of Justice investigation into UnitedHealth's Medicare Advantage practices is also a concern, as it has the potential to impact the company's stock price regardless of its financial performance.